Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience

S. Chiara, S. Mammoliti, C. Oliva, L. Merlini, M. Bruzzone, M. R. Sertoli, G. C. Parodi, N. Ragni, G. Foglia, F. Odicino, G. Parodi, L. Iskra, F. Carnino, E. Guercio, P. F. Conte, R. Rosso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs G2 vs. G3: P <0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.

Original languageEnglish
Pages (from-to)1211-1215
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number10
DOIs
Publication statusPublished - 1991

Fingerprint

Ovarian Neoplasms
Cisplatin
Recurrence
Drug Therapy
Survival
Adjuvant Chemotherapy
Cyclophosphamide
Vomiting
Carcinoma
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer : a 7-year experience. / Chiara, S.; Mammoliti, S.; Oliva, C.; Merlini, L.; Bruzzone, M.; Sertoli, M. R.; Parodi, G. C.; Ragni, N.; Foglia, G.; Odicino, F.; Parodi, G.; Iskra, L.; Carnino, F.; Guercio, E.; Conte, P. F.; Rosso, R.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 10, 1991, p. 1211-1215.

Research output: Contribution to journalArticle

Chiara, S, Mammoliti, S, Oliva, C, Merlini, L, Bruzzone, M, Sertoli, MR, Parodi, GC, Ragni, N, Foglia, G, Odicino, F, Parodi, G, Iskra, L, Carnino, F, Guercio, E, Conte, PF & Rosso, R 1991, 'Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience', European Journal of Cancer and Clinical Oncology, vol. 27, no. 10, pp. 1211-1215. https://doi.org/10.1016/0277-5379(91)90083-P
Chiara, S. ; Mammoliti, S. ; Oliva, C. ; Merlini, L. ; Bruzzone, M. ; Sertoli, M. R. ; Parodi, G. C. ; Ragni, N. ; Foglia, G. ; Odicino, F. ; Parodi, G. ; Iskra, L. ; Carnino, F. ; Guercio, E. ; Conte, P. F. ; Rosso, R. / Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer : a 7-year experience. In: European Journal of Cancer and Clinical Oncology. 1991 ; Vol. 27, No. 10. pp. 1211-1215.
@article{9b276b5e5fa34fc393ad688716e5fee0,
title = "Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience",
abstract = "87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10{\%} of patients) and controllable grade 3 emesis (55{\%}). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76{\%} and 61{\%}, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs G2 vs. G3: P <0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.",
author = "S. Chiara and S. Mammoliti and C. Oliva and L. Merlini and M. Bruzzone and Sertoli, {M. R.} and Parodi, {G. C.} and N. Ragni and G. Foglia and F. Odicino and G. Parodi and L. Iskra and F. Carnino and E. Guercio and Conte, {P. F.} and R. Rosso",
year = "1991",
doi = "10.1016/0277-5379(91)90083-P",
language = "English",
volume = "27",
pages = "1211--1215",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer

T2 - a 7-year experience

AU - Chiara, S.

AU - Mammoliti, S.

AU - Oliva, C.

AU - Merlini, L.

AU - Bruzzone, M.

AU - Sertoli, M. R.

AU - Parodi, G. C.

AU - Ragni, N.

AU - Foglia, G.

AU - Odicino, F.

AU - Parodi, G.

AU - Iskra, L.

AU - Carnino, F.

AU - Guercio, E.

AU - Conte, P. F.

AU - Rosso, R.

PY - 1991

Y1 - 1991

N2 - 87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs G2 vs. G3: P <0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.

AB - 87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs G2 vs. G3: P <0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.

UR - http://www.scopus.com/inward/record.url?scp=0025949301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025949301&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90083-P

DO - 10.1016/0277-5379(91)90083-P

M3 - Article

C2 - 1835588

AN - SCOPUS:0025949301

VL - 27

SP - 1211

EP - 1215

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -